Scholar Commons
metadata only
Cost-Effectiveness of Donanemab and Lecanemab Over a Lifetime Horizon for Patients with Early Alzheimers Disease
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics#161197
- Safety and short-term outcomes of lecanemab for Alzheimer's disease in China: a multicentre study.#260287
- Use of a Brief Phone Call After ED Discharge#1153840
- Economic Analysis of Alliance A041202 CLL Study#879933
- An Open-Label Crenezumab Study in Participants With Alzheimer's Disease#1162908
Record · ID 323896
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive